High Cholesterol

About High Cholesterol Clinical Trials (Click to Open)

Join Clinical Trials for High Cholesterol

clinical trials for high cholesterolGeneral Purpose:

Though high cholesterol on its own may not have symptoms, those with it are more prone to developing coronary heart disease. Lowering your cholesterol is a critical step in preventing heart disease and blood clots. This condition is treated with medications and behavioral changes, such as diet and exercise.

The aim of clinical research is to find new and improved treatments, generally to lower your low-density lipoprotein (LDL) cholesterol level, as it is increased LDL levels that increase your risk for developing heart disease, having a heart attack, and other serious health threats.

Certain trials are attempting to expand the scientific knowledge of these lipoproteins, to better understand the factors that affect these levels. In observational studies as this, you may not personally benefit by participating, but you will help researchers develop improved diagnostic and treatment measures for individuals with high cholesterol.

Moreover, given that high cholesterol is often associated with other diseases, many clinical trials will be monitoring cholesterol levels in relation to such diseases as heart disease and diabetes. Though some studies will specifically be looking at dyslipidemia (high blood cholesterol levels), in order to assess improved medications or behavioral programs.

What will High Cholesterol Clinical Trials be like?

Before joining a clinical trial, researchers will first assess your eligibility. You will go through a screening phase to ensure that you are an appropriate participant for the aims of the trial. Since there are many crossover trials with other diseases, you may gain the most benefit by joining a study that involves another condition that you also have.

Moreover, if a trial is looking at a potential relationship between a vitamin deficiency and high cholesterol, they will likely only include individuals with both conditions. The goal of these trials is to lower cholesterol and prevent individuals with high cholesterol from developing more serious conditions, so inclusion criteria is put in place to facilitate this benefit and avoid wasting your time.

They are also put in place to avoid any risk of a detrimental interaction between a behavioral or pharmaceutical intervention and an existing condition or medication. The researchers will therefore ask you to provide a very detailed medical history.

Typical High Cholesterol Clinical Trial Protocol:

If the main interventional method being tested is a new pharmaceutical, you will be clinical trials for high cholesterolrandomly assigned to a group that either receives a varying dose of the treatment or a placebo. To evaluate this intervention, participants may be asked to visit for follow up examinations and/or take follow up questionnaires.

Lifestyle plays a contributive role on cholesterol levels; many trials intend to uncover the most beneficial behavioral changes for individuals with high cholesterol. Participants will undergo relevant baseline assessments, and continuous monitoring throughout the trial.

These trials will attempt to provide you personal benefit to reduce your cholesterol levels and risk of heart disease, as well benefit others struggling with high cholesterol.

Suggested Search Terms:

Lowering Cholesterol Levels, Dyslipidemia, High Cholesterol and Hypertension, Reducing the Risk of Heart Disease, Evaluation of Lipoproteins 

Current Search Term:

High Cholesterol

Add Comments or Questions



Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: evolocumab;   Drug: evolocumab and LDL apheresis;   Procedure: LDL apheresis
Sponsor:   Hospital General Universitario Gregorio Marañon
Completed


Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy


Condition:   Hypercholesterolaemia
Interventions:   Drug: Alirocumab SAR236553;   Device: Current auto-injector device (AI);   Device: New auto-injector device (SYDNEY)
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Not yet recruiting


HS-25 and Placebo for Adults With Primary Hypercholesterolemia


Condition:   Primary Hypercholesterolemia
Interventions:   Drug: HS-25;   Drug: Placebo of HS-25
Sponsor:   Zhejiang Hisun Pharmaceutical Co. Ltd.
Active, not recruiting


Safety and Tolerability of Repatha in Indian Subjects With Homozygous Familial Hypercholesterolemia


Condition:   Homozygous Familial Hypercholesterolemia HoFH
Intervention:   Drug: Repatha® (evolocumab)
Sponsor:   Amgen
Not yet recruiting


A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: HTD1801 Tablets, 500mg;   Drug: HTD1801 Tablets, 1000mg;   Drug: HTD1801 Tablets, 2000mg
Sponsor:   HighTide Biopharma Pty Ltd
Not yet recruiting


The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: Rosuvastatin;   Drug: Ezetimibe
Sponsor:   Shin Poong Pharmaceutical Co. Ltd.
Completed


Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: Evinacumab;   Drug: Matching placebo;   Other: Background Lipid Modifying Therapy (LMT)
Sponsor:   Regeneron Pharmaceuticals
Not yet recruiting


Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: alirocumab SAR236553 (REGN727);   Drug: placebo for alirocumab;   Drug: ezetimibe;   Drug: placebo for ezetimibe;   Drug: atorvastatin;   Drug: rosuvastatin;   Drug: simvastatin
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting


Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Dietary Supplement: Lactoflorene colesterolo;   Dietary Supplement: Placebo lactoflorene colesterolo
Sponsor:   Montefarmaco OTC SpA
Completed


A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins


Condition:   Hypercholesteremia
Interventions:   Drug: Gemcabene 600 mg;   Drug: Placebo
Sponsor:   Gemphire Therapeutics, Inc.
Completed


A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia


Condition:   Hypercholesterolemia
Interventions:   Drug: CAT-2054;   Drug: Placebo;   Drug: Atorvastatin
Sponsor:   Catabasis Pharmaceuticals
Completed


A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)


Condition:   Hypercholesterolemia
Interventions:   Drug: Ezetimibe 10 mg;   Drug: Atorvastatin 10 mg;   Drug: Placebo for Ezetimibe 10 mg tablet;   Drug: Placebo for Atorvastatin 10 mg capsule;   Behavioral: Diet control/Daily Exercise
Sponsor:   Merck Sharp & Dohme Corp.
Completed


French Observatory of Familial Hypercholesterolemia in Cardiology


Condition:   Familial Hypercholesterolemia
Intervention:  
Sponsor:   French Cardiology Society
Suspended


Study of Awareness and Detection of Familial Hypercholesterolemia


Condition:   Hypercholesterolemia
Intervention:  
Sponsors:   The Familial Hypercholesterolemia Foundation;   Duke Clinical Research Institute
Recruiting


A Study of LY3015014 in Participants With High Cholesterol


Condition:   Hypercholesterolemia
Interventions:   Drug: LY3015014;   Drug: Placebo;   Drug: Statin;   Drug: Ezetimibe
Sponsor:   Eli Lilly and Company
Completed


The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository


Condition:   Homozygous Familial Hypercholesterolemia
Intervention:  
Sponsor:   The Rogosin Institute
Recruiting


Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)


Condition:   Primary Hypercholesterolemia
Interventions:   Drug: ezetimibe;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed


A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)


Condition:   Hypercholesterolemia
Interventions:   Drug: Atorvastatin 10 mg;   Drug: Ezetimibe 10 mg/simvastatin 20 mg;   Drug: Atorvastatin 20 mg;   Drug: Ezetimibe 10 mg/simvastatin 40 mg;   Drug: Atorvastatin 40 mg
Sponsors:   Merck Sharp & Dohme Corp.;   Merck Shering-Plough JV Study
Completed


A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)


Condition:   Hypercholesterolemia
Interventions:   Drug: ezetimibe (+) simvastatin;   Drug: Comparator : rosuvastatin calcium;   Drug: Comparator: Placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed


A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)


Condition:   Hypercholesterolemia
Interventions:   Drug: ezetimibe;   Drug: Comparator: placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed


A Study of MK0653A (Ezetimibe (+) Simvastatin) in Patients With Hypercholesterolemia (0653A-038)


Condition:   Hypercholesterolemia
Interventions:   Drug: MK0653A, ezetimibe (+) simvastatin;   Drug: Comparators: simvastatin and ezetimibe
Sponsor:   Merck Sharp & Dohme Corp.
Completed


An Extension Study of An Investigational Drug in Patients With Hypercholesterolemia (0653A-038)(COMPLETED)


Condition:   Hypercholesterolemia
Intervention:   Drug: MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks
Sponsor:   Merck Sharp & Dohme Corp.
Completed


MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)


Condition:   Hypercholesterolemia
Interventions:   Drug: MK0653A, ezetimibe (+) simvastatin;   Drug: Comparator: atorvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Study of an Approved Drug With a Statin (a Medication That Lowers Cholesterol Levels) as Compared to Statin Therapy Alone in Patients With High Cholesterol (0653-040)


Condition:   Hypercholesterolemia
Interventions:   Drug: MK0653, ezetimibe;   Drug: Comparator: statins
Sponsor:   Merck Sharp & Dohme Corp.
Completed


Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)


Condition:   Hypercholesterolemia
Interventions:   Drug: MK0733, simvastatin;   Drug: Comparator: simvastatin
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Refine Your Search Advanced Search